CN1969892A - Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and quality control method thereof - Google Patents
Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and quality control method thereof Download PDFInfo
- Publication number
- CN1969892A CN1969892A CN 200510115004 CN200510115004A CN1969892A CN 1969892 A CN1969892 A CN 1969892A CN 200510115004 CN200510115004 CN 200510115004 CN 200510115004 A CN200510115004 A CN 200510115004A CN 1969892 A CN1969892 A CN 1969892A
- Authority
- CN
- China
- Prior art keywords
- folium ginkgo
- troxerutin
- injection
- pharmaceutical composition
- ginkgo total
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a drug composition and making method and quality control method to treat cardiovascular and cerebrovascular disease, which is composed of one or two composition of birutan and ginkgo leaf flavone or lactone to make kinds of injection or oral agent.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease and preparation method thereof and quality control method, belong to technical field of medicaments.
Technical background
Cardiovascular and cerebrovascular disease such as coronary heart disease, angina pectoris, cerebral thrombosis etc. all are one of the most common and diseases that harm is maximum in the world today, have become human mortality's one of the main reasons in many countries; Prevent and treat purpose in order to reach, a large amount of research has been done by many inventors and medicine enterprise, and the Chinese medicine and western medicine product appears on the market in a large number; Although the disease that they are used for the treatment for the treatment of cardiac and cerebral vascular diseases has certain curative effect; But in long-term clinical application, find, the Western medicine side effect is bigger, be not suitable for taking for a long time, a large amount of Chinese traditional medicine biology availabilities are low, owing to be used as medicine with Chinese crude drug mostly, the influence factor is more simultaneously, cause the curative effect fluctuation bigger, therefore, searching is better, therapeutic effect is desirable, and little, the quality controllable effective medicine of toxic and side effects has just become people's urgent problem.
The inventor furthers investigate discovery, employing effective site is used as medicine, can not only reduce patient's dose, remove the strong composition of some toxic and side effects in the medicinal substances extract, improve the safety of preparation and the controllability of quality, greatly improve curative effect, and more help the molding of preparation, some unnecessary technologies in the forming process have been reduced, contrast after deliberation, we develop a kind of preparation for the treatment of cardiovascular and cerebrovascular disease, mainly by one or both prescriptions of troxerutin and Folium Ginkgo total flavones, Folium Ginkgo total lactones.Folium Ginkgo is as conventional Chinese medicine, and medicinal history is long, and the object of study of cardiovascular and cerebrovascular vessel field the supreme arrogance of a person with great power especially in recent years be widely used in the treatment of cardiovascular and cerebrovascular disease as SHUXUENING ZHUSHEYE, and market sale ranks preceding lance always; Troxerutin has the erythrocyte of inhibition, platelet aggregation, prevent thrombosis, increase blood oxygen saturation, microcirculation improvement, promote neovascularity to generate, promote side Zhi Xunhuan, effects such as cerebral blood flow increasing amount, but consolidate curative effect not as people's will, anaphylaxis is arranged simultaneously, untoward reaction such as flushing, headache and gastrointestinal upset take place, so the inventor, finds that both prescriptions can the Synergistic attenuation by comparative study.For this reason, the applicant furthers investigate, one or both of employing Folium Ginkgo total flavones or Folium Ginkgo total lactones are used as medicine, the compatibility troxerutin, the proportion compatibility of research screening and troxerutin optimum, further study preparations shaping and stability problem, and then select for the patient provides a new medication.
Summary of the invention
The objective of the invention is to: a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease and preparation method thereof and quality control method are provided; At prior art, according to cardiovascular and cerebrovascular disease such as coronary heart disease, cerebral thrombosis, alzheimer disease etc. all contract because of blood vessel is narrow, reason such as blood flow minimizing causes the diseases induced principle of blood supply insufficiency, on the basis of experiment screening, adopt one or both compatibilities of troxerutin and Folium Ginkgo total flavones, Folium Ginkgo total lactones to make preparation, optimize best prescription and technology; The product that obtains, can not only restrain platelet aggregation, simultaneously blood circulation promoting and blood stasis dispelling, TONGMAI SHULUO, improve blood circulation and metabolism, treating both the principal and secondary aspects of a disease, Synergistic, for example coronary heart disease is that coronary atherosclerosis causes myocardial ischemia, anoxia and the heart disease that causes, two medicines share, and can play and improve myocardial metabolism effect, increase coronary flow, improve blood supply of cardiac muscle to improve clinical symptoms and sign.The present invention has curative effect preferably for treating cardiovascular and cerebrovascular disease such as coronary heart disease, angina pectoris, arrhythmia, cerebral thrombosis, alzheimer disease etc.Preparation of the present invention has tangible efficacy enhancing and toxicity reducing effect simultaneously, and its safety range is big, but the little patients life-time service of untoward reaction.
The present invention constitutes like this:
A kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease calculates according to parts by weight, and it is mainly to be made up of for 0.1～30 part 1 part of troxerutin and 0.1～50 part of Folium Ginkgo total flavones or 0.01～50 part of Folium Ginkgo total lactones or Folium Ginkgo total flavones and total lactone.Say accurately, calculate that it mainly is made up of for 0.1～15 part 1 part of troxerutin and 0.5～20 part of Folium Ginkgo total flavones or 0.1～10 part of Folium Ginkgo total lactones or Folium Ginkgo total flavones and total lactone according to parts by weight.Preferably, calculate according to parts by weight, it mainly is made up of for 0.2～5 part 1 part of troxerutin and 1～10 part of Folium Ginkgo total flavones or 0.2～5 part of Folium Ginkgo total lactones or Folium Ginkgo total flavones and total lactone.
Described combination dosage form be directly used in the injection of drug administration by injection, directly for the venous transfusion of intravenous drip, need to be used for after the dilution all acceptable dosage forms on the pharmaceuticss such as the concentrated solution for injection of intravenous drip and the injectable sterile powder that makes with freeze-drying or spray drying method and aseptic block and tablet, capsule, granule, drop pill, pellet, pill, soft capsule, oral liquid, oral cavity disintegration tablet, dispersible tablet, membrane, sublingual lozenge.Preferably, described combination dosage form comprise the injection that is directly used in drug administration by injection, directly for the venous transfusion of intravenous drip, need to be used for after the dilution concentrated solution for injection of intravenous drip and the injectable sterile powder that makes with freeze-drying or spray drying method and aseptic block and drop pill, pellet, oral liquid, oral cavity disintegration tablet, dispersible tablet, sublingual lozenge.
Described composite preparation can make on the basis that in troxerutin, Folium Ginkgo total flavones, the Folium Ginkgo total lactones one or more is prepared into liposome or pro-liposome.
Folium Ginkgo effective site is commercially available or adopts following method to prepare: get the Folium Ginkgo medical material, adding entry or alcoholic solution extracts, merge extractive liquid,, filter, filtrate concentrate the Radix Puerariae crude extract, adopt on this basis ethanol precipitation, water return in molten method, column chromatography, extraction, the flocculent precipitation one or more unite use carry out suitably refining, Folium Ginkgo total flavones effective site; Get the Folium Ginkgo medical material, adding entry or alcoholic solution extracts, merge extractive liquid,, filter, filtrate concentrate the Radix Puerariae crude extract, adopt on this basis ethanol precipitation, water return in molten method, column chromatography, extraction, the flocculent precipitation one or more unite use carry out suitably refining, Folium Ginkgo total lactones effective site.
The content sum of flavones ingredient and lactone composition is not less than in the preparation 50% of total solid after deduction troxerutin amount, pharmaceutical adjunct amount and the water quantities in the oral formulations, and the content sum of flavones ingredient and lactone composition is not less than 70% of total solid after deduction troxerutin amount, pharmaceutical adjunct amount and the water quantities in the ejection preparation; Troxerutin content should be 90.0%～110.0% of preparation labelled amount.
The Injectable sterile block prepares like this: one or both that get troxerutin and Folium Ginkgo total flavones, Folium Ginkgo total lactones add injection and blunge and make dissolving, filter, filtrate is boiled the active carbon that the back adds 0.6% (W/V), keeping little boiled 30 minutes, cold slightly filtration, boil filtrate adjust pH to 4.5～6.0, coarse filtration, fine straining are spent the night in cold preservation (4 ℃); Mannitol is added the injection water be mixed with 120mg/ml solution,, filter, add the injection water, packing, lyophilization, pre-freeze temperature-45 ℃, pre-freeze time 10h to ormal weight with above-mentioned filtrate mixing; The beginning evacuation, and be warming up to-40 ℃, keep 8h; And in 12～72 hours differential gradient increased temperature to 10 ℃ progressively, keep 2h, be warming up to 20 ℃, keep 2h, be warming up to 30 ℃, keep 2h, promptly.
Described compositions is used for the treatment of coronary heart disease, angina pectoris, cerebral thrombosis, alzheimer disease, cerebral vasospasm, thrombophlebitis, capillary hemorrhage, arteriosclerosis, diabetes and diseases such as complication, hepatorenal syndrome thereof.
The method of quality control of the pharmaceutical composition of described treatment cardiovascular and cerebrovascular disease comprises following all or part of content:
(1) finger printing test comprises that being characterized as the Folium Ginkgo terpene lactone constituents of advocating peace with the Folium Ginkgo flavone constituents is characterized as one or both of main finger printing;
(2) all or part of differential test method in Folium Ginkgo medical material, total flavonoids, terpene lactone, the troxerutin;
(3) content test method of all or part of composition in total flavonoids, terpene lactone, the troxerutin.
Compared with prior art, the applicant carried out lot of experiments, and the best compatibility scope that filters out troxerutin and Folium Ginkgo total flavones is 1 part of troxerutin and 1～10 part of Folium Ginkgo total flavones.Adopt good, the steady quality of prepared product appearance of the present invention.
For proving that medicine provided by the invention has effective effect, the applicant has carried out a series of experiments.
Experimental example 1: to the comparative study of different proportioning pharmacodynamics
1, thrombotic model test due to the medicine method
144 of healthy male mices; body weight 25～35g; be divided into 9 groups; grouping sees the following form, and 16 every group, gives relative medicine shown in the according to the form below; the derivant that mixes of gastric infusion tail vein injection collagen protein after 1 hour (250 μ g/ only) and epinephrine (9 μ g/); promptly observe dead mouse number within 5 minutes after the injection or the not recovery number of mice hemiplegia in 15 minutes, calculate the protective rate of medicine, the results are shown in Table 1 the mouse brain thrombosis.
The influence that the inductive mice thrombus in vivo of table 1 pair collagen protein-epinephrine forms
| Group | Mus number (only) | Recover number (only) in the 15min | Recovery rate (%) |
| The normal saline group | 16 | 0 | 0 |
| Troxerutin injection group | 16 | 10 | 62.5 |
| The SHUXUENING ZHUSHEYE group | 16 | 9 | 56.3 |
| Folium Ginkgo total flavones-troxerutin group 50: 1 | 16 | 11 | 68.8 |
| Folium Ginkgo total flavones-troxerutin group 20: 1 | 16 | 12 | 75 |
| Folium Ginkgo total flavones-troxerutin group 10: 1 | 16 | 14 | 87.5 |
| Folium Ginkgo total flavones-troxerutin group 1: 1 | 16 | 15 | 93.8 |
| Folium Ginkgo total flavones-troxerutin group 0.5: 1 | 16 | 13 | 81.3 |
| Folium Ginkgo total flavones-troxerutin group 0.1: 1 | 16 | 12 | 75 |
As shown in Table 1, the medicine of Folium Ginkgo total flavones and the different proportionings of troxerutin all has protective effect to the inductive mice thrombus in vivo of collagen protein-epinephrine, and the strong and weak degree of this effect is relevant with the proportioning of medicine.Wherein with Folium Ginkgo total flavones: troxerutin=1～10: 1 prescription pharmacological action is strong and consumption is lower.
2, to the influence of rabbit platelet aggregation
Get 45 of rabbit, body weight 3～5kg, male, be divided into 9 groups, grouping sees the following form, 5 every group, give relative medicine shown in the according to the form below, measure surface activity of blood platelet and aggregation from heart extracting blood before the administration, in auricular vein injection relative medicine or equivalent normal saline, check surface activity of blood platelet or aggregation after 1 hour.The results are shown in Table 2.
The influence of table 2 pair platelet aggregation
| In 50: 1 ginkgo biloba leaf totals of group physiological saline group troxerutin injection group Shu Xuening injection group ginkgo biloba leaf total terpene lactone-Troxerutin group | Before circle tree type (%) administration after the administration 70.2 ± 73.4 ± 2.53 3.16 71.2 ± 82.3 ± 3.58 4.22 73.0 ± 80.1 ± 3.27 2.38 72.5 ± 84.6 ± 4.58 3.87 72.6 ± 86.5 ± | Before expansion type (%) administration after the administration 29.8 ± 26.6 ± 2.53 3.16 28.8 ± 17.7 ± 3.58 4.22 27.0 ± 19.9 ± 3.27 2.38 27.5 ± 15.4 ± 4.58 3.87 27.4 ± 13.5 ± | Before aggregation number (individual) administration after the administration 60.2 ± 58.4 ± 3.42 3.58 61.5 ± 52.8 ± 2.39 4.27 63.2 ± 55.7 ± 4.82 4.49 62.4 ± 50.8 ± 3.51 5.34 61.8 ± 47.7 ± |
| 0.1: 1 ginkgo biloba leaf total terpene lactone of 0.2: 5 ginkgo biloba leaf total terpene lactone of 5: 1 ginkgo biloba leaf total terpene lactones of 10: 1 ginkgo biloba leaf total terpene lactones of ester-Troxerutin group-Troxerutin group-Troxerutin group-Troxerutin group-Troxerutin group 0.01: 1 | 5.11 7.24 71.3± 88.2± 5.69 6.24 70.9± 89.5± 4.23 5.67 73.2± 86.7± 5.68 4.26 72.5± 83.9± 3.24 5.28 | 5.11 7.24 28.7± 11.8± 5.69 6.24 29.1± 10.5± 4.23 5.67 26.8± 13.3± 5.68 4.26 17.5± 16.1± 3.24 5.28 | 4.28 6.49 60.4± 42.3± 4.56 5.27 61.9± 40.8± 5.21 7.26 60.7± 45.2± 3.21 5.26 62.9± 51.3± 2.56 6.02 |
As shown in Table 2, the medicine of Folium Ginkgo total lactones and the different proportionings of troxerutin can significantly reduce surface activity of blood platelet or aggregation effect, and the strong and weak degree of this effect is relevant with the proportioning of medicine.
Table 1, table 2 show: Folium Ginkgo total flavones or Folium Ginkgo total lactones compatibility troxerutin can produce synergistic function, drug effect all is significantly improved than singly using with dosage troxerutin or Folium Ginkgo total flavones or total lactone, the medicine of troxerutin and Folium Ginkgo total flavones or the different proportionings of Folium Ginkgo total lactones all can significantly increase curative effect, but the strong and weak degree of effect is relevant with the proportioning of medicine; From interpretation, the optimum range of Folium Ginkgo total flavones and troxerutin is: 1 part of troxerutin, 1～10 part of Folium Ginkgo total flavones; The optimum range of Folium Ginkgo total lactones and troxerutin is: 1 part of troxerutin, 0.2～5 part of Folium Ginkgo total lactones.
Experimental example 2: injection Study on Forming
2.1 activated carbon dosage is investigated:
Injection owing to solvent, raw material, container etc. have the pyrogen material, reduces the safety of injection in the process of producing, and therefore needs to remove the pyrogen material in the process of preparation injection.The method of depyrogenation mainly contains high temperature method, acid-base method, ultrafiltration and absorption method at present, active carbon adsorption not only can heat of adsorption originality composition, the effect that also has filter of helping and decolouring, when removing pyrogen, can improve the appearance character of preparation, therefore we select the active carbon adsorption depyrogenation for use, and its consumption investigated, the results are shown in following table.
The activated carbon dosage investigation table
Activated carbon dosage (%) the total flavones rate of transform (%) outward appearance
0.1 86.7 is reddish brown
0.6 80.5 is red
1.2 75.3 is red
From the medicinal liquid outward appearance, select activated carbon dosage be 0.6% and 1.2% proper; But judge that from the rate of transform 0.1% consumption and 0.6% consumption are slightly better, the three all can satisfy the related request of injection, but takes all factors into consideration above factor, so that be the best with the activated carbon decolorizing of medicine liquid volume 0.6%.
2.2 pH value of solution is investigated
For adapting to the Human Physiology needs, also to consider the character of each constituents in the medicinal liquid simultaneously, when dosing, need suitably adjust the pH value of medicinal liquid.Select the total flavones rate of transform as evaluation index.
Test method and result: after feeding intake and handle by recipe quantity by above-mentioned condition, with the concentrated solution mix homogeneously, filter, add water to 1000ml, adjust pH when the different pH value that reaches shown in the following table, boils the back standing over night, the variation of observation appearance character under different pH condition, experimental result sees Table.
The investigation of dosing pH value (is to investigate index with the outward appearance)
Sequence number 12345678
Dosing pH 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5
Boil pH 3.5 4.3 4.7 5.3 5.8 5.9 6.3 6.8
The no significant change color burn of precipitation appears in outward appearance
The result shows, medicinal liquid boils the back pH value and occurs precipitating at the sample 4.5 below, and pH value is obviously deepened in the color sample more than 6.0, and pH value is that 4.5～6.0 medicinal liquid is relatively stable, and outward appearance does not have significant change.Below its Folium Ginkgo total flavones rate of transform is measured, be the results are shown in Table.
The investigation of dosing pH value (is index with the total flavones rate of transform)
| Sequence number | Dosing pH | Rate of transform during dosing (%) | Boil back pH | Boil the back rate of transform (%) |
| 1 | 5.5 | 85.6 | 5.2 | 83.1 |
| 2 | 6.0 | 85.6 | 5.7 | 83.6 |
| 3 | 6.5 | 85.6 | 6.3 | 84.8 |
| 4 | 7.0 | 85.6 | 6.7 | 85.4 |
As seen from table, medicinal liquid is being adjusted the pH value front and back, the not too big variation of the index components total flavones rate of transform.The appearance character of comprehensive above-mentioned medicinal liquid and the total flavones rate of transform, the pH value of medicinal liquid is transferred between 4.5～6.0 when determining dosing.
2.3 the screening of freeze-dried powder caffolding agent kind
The caffolding agent kind influences the molding of freeze-dried powder, so at first this is screened.Taking liquid mixes with caffolding agent mannitol, glucose and lactose solution respectively, 0.22 μ m membrane filtration postlyophilization, every XiLin bottle-packaging solution 3ml.Freeze dryer: Edwards SNL-3200 freezer dryer (the thermoelectric Thermo of the U.S.).Lyophilisation condition :-45 ℃, behind the pre-freeze 8h, the beginning evacuation, and be warming up to-40 ℃, keep 10h; Be warming up to-30 ℃, keep 10h; Be warming up to-20 ℃, keep 10h; Be warming up to-10 ℃, keep 5h; Be warming up to 0 ℃, keep 5h; Be warming up to 15 ℃, keep 3h; Be warming up to 25 ℃, keep 3h, the result is as table.
The screening of caffolding agent kind
| Caffolding agent kind galactose mannitol glycine dextran mannitol, the propylene glycol dextran, sorbitol, the blank medicinal liquid of tween | Caffolding agent: soup (V: V) 2: 12: 12: 12: 12: 12: 1 3ml | Solubility is generally good general carefully general | The moulding moulded moulding of finished product outward appearance, frangible moulding moulded moulding atrophy |
As seen from table, in the adjuvant that is screened, under the identical situation of other conditions, most of adjuvant all can be made into freeze-dried powder, but solubility angle integrated survey from yield rate, molding situation and sample, use the effect of mannitol to be better than other several adjuvants separately, can satisfy the every requirement of injection, reduce simultaneously as far as possible and add too much adjuvant.
Embodiment 3: the dispersible tablet disintegrating agent is selected
The disintegrating agent that dispersible tablet is commonly used has low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone etc.They have very strong imbibition as disintegrating agent, function admirable, and have that bulk density is little, specific surface area is big, good fluidity, be easy to characteristics such as dispersion in prescription.So initial option this two material is as the disintegrating agent of this product, and further investigates its usage and dosage in this preparation, result of the test sees the following form.Mix 0.22 μ m membrane filtration postlyophilization, every XiLin bottle-packaging solution 3ml with caffolding agent mannitol, glucose and lactose solution.Freeze dryer: Edwards SNL-3200 freezer dryer (the thermoelectric Thermo of the U.S.).Lyophilisation condition :-45 ℃, behind the pre-freeze 8h, the beginning evacuation, and be warming up to-40 ℃, keep 10h; Be warming up to-30 ℃, keep 10h; Be warming up to-20 ℃, keep 10h; Be warming up to-10 ℃, keep 5h; Be warming up to 0 ℃, keep 5h; Be warming up to 15 ℃, keep 3h; Be warming up to 25 ℃, keep 3h, the result is as table.
The screening of caffolding agent kind
| Caffolding agent kind galactose mannitol glycine dextran mannitol, the propylene glycol dextran, sorbitol, the blank medicinal liquid of tween | Caffolding agent: soup (V: V) 2: 12: 12: 12: 12: 12: 1 3ml | Solubility is generally good general carefully general | The moulding moulded moulding of finished product outward appearance, frangible moulding moulded moulding atrophy |
As seen from table, in the adjuvant that is screened, under the identical situation of other conditions, most of adjuvant all can be made into freeze-dried powder, but solubility angle integrated survey from yield rate, molding situation and sample, use the effect of mannitol to be better than other several adjuvants separately, can satisfy the every requirement of injection, reduce simultaneously as far as possible and add too much adjuvant.
Embodiment 3: the dispersible tablet disintegrating agent is selected
The disintegrating agent that dispersible tablet is commonly used has low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone etc.They have very strong imbibition as disintegrating agent, function admirable, and have that bulk density is little, specific surface area is big, good fluidity, be easy to characteristics such as dispersion in prescription.So initial option this two material is as the disintegrating agent of this product, and further investigates its usage and dosage in this preparation, result of the test sees the following form.Quantitative glucose or sodium chloride by volume add 0.6% active carbon behind the mixed dissolution, boil, keep little 30min that boils, cold slightly filtration, filtrate adds the injection water to ormal weight, adjust pH to 4.5～5.0, boil, 4 ℃ of cold preservations are spent the night, coarse filtration, fine straining, add the injection water, packing, sterilization promptly gets glucose or sodium chloride intravenous infusion.
Embodiments of the invention 4: troxerutin 10g Folium Ginkgo total flavones, total lactone 500g
Getting troxerutin, Folium Ginkgo total flavones, total lactone adds injection and blunges and make dissolving, filter, filtrate adds 0.56% needle-use activated carbon, boiled 30 minutes, coarse filtration, reuse 0.45 μ m and 0.22 μ m microporous filter membrane filter, divide and install in the enamel tray, lyophilization, the equilibration time when the balance solidification point of phase I is 0 ℃ is 1.5 hours, i.e. the time of shelf temperature and product temperature basically identical; The second stage solidification point is from 0 ℃ during to minimum eutectic temperature-16 ℃, and shelf temperature and product temperature equilibration time are 2 hours; Phase III continues to be cooled to-40 ℃, need 2 hours approximately, kept this temperature 2 hours, freeze the jail fully until product, promptly begin evacuation, enter drying program, under-40 ℃ of constant temperature-evacuation, slowly heat up, 2～4 ℃/h, to the lowest total of the melting point temperature, time is about 12 hours, after sublimation drying is finished, continue under the low pressure condition, it is dry to remove residual moisture to heat up, time is about 14～16 hours, kept more than 35 ℃ dry 1.5 hours, and under aseptic condition, divided to install in the cillin bottle, promptly get injectable sterile powder.
Embodiments of the invention 5: troxerutin 10g Folium Ginkgo total flavones 1g
Get troxerutin, Folium Ginkgo total flavones, mixing adds an amount of water for injection dissolving, by volume add 0.6% active carbon, boil, keep little 30min that boils, cold slightly filtration, filtrate add the injection water to ormal weight, pH value to 4.5～6.0, boil, 4 ℃ of cold preservations are spent the night, and coarse filtration, fine straining are 165 ℃ in inlet temperature, leaving air temp is 55 ℃, and air velocity is 20ms
-1Condition under spray drying get powder, packing promptly gets injectable sterile powder.
Embodiments of the invention 6: troxerutin 10g Folium Ginkgo total flavones 5g
With troxerutin and Folium Ginkgo total flavones mix homogeneously, it is an amount of to add polyvinylpolypyrrolidone, microcrystalline Cellulose, Rhizoma Steudnerae Henryanae essence, and compacting promptly gets oral cavity disintegration tablet in flakes.
Embodiments of the invention 7: troxerutin 3g Folium Ginkgo total lactones 60g
With troxerutin and Folium Ginkgo total lactones mix homogeneously, to be that 2: 1 Macrogol 4000 is put in the rustless steel container with the principal agent ratio, add medicated powder, mix homogeneously, be heated to 80～90 ℃, after treating whole fusions, 70～80 ℃ of insulations are transferred in the reservoir, 70～80 ℃ of insulations, regulate the dropping liquid valve, splash in 30～40 ℃ the dimethicone or liquid paraffin, drip apart from 5～6cm, drip 40～45 droplets/minute of speed, dimethicone or liquid paraffin are use up and wiped to the drop pill drop that forms, and packing promptly gets drop pill.
Embodiments of the invention 8: troxerutin 1g Folium Ginkgo total lactones 5g
With troxerutin and Folium Ginkgo total lactones mix homogeneously, in principal agent: the ratio of adjuvant=1: 2 adds calcium hydrogen phosphate, and by principal agent: adjuvant=ratio of 1: 2 adds the mixed accessories of low-substituted hydroxypropyl cellulose and crospolyvinylpyrrolidone (1: 1), and is mixed even, the system soft material, granulate drying, granulate, add an amount of Pulvis Talci, micropowder silica gel, evenly mixed, tabletting promptly gets dispersible tablet.
Embodiments of the invention 9: troxerutin 10g Folium Ginkgo total flavones, total lactone 2g
With troxerutin, Folium Ginkgo total flavones mixing, drying adds appropriate amount of starch, ethanol with 65% and 1.4% soybean oil system soft material, and extruding-round as a ball pill selects ball, and drying promptly gets pellet.
Embodiments of the invention 10: troxerutin 1g Folium Ginkgo total lactones 10g
With troxerutin and Folium Ginkgo total flavones mix homogeneously, add starch, stevioside, microcrystalline Cellulose is an amount of, granulates, drying, granulate promptly gets granule.
Embodiments of the invention 11: troxerutin 1g Folium Ginkgo total flavones, total lactone 5g
With troxerutin and Folium Ginkgo total flavones, total lactone mix homogeneously, add starch, the dextrin of equivalent, mix homogeneously is granulated, and is encapsulated, promptly gets capsule.
Embodiments of the invention 12: troxerutin 100g Folium Ginkgo total lactones 10g
Get troxerutin and Folium Ginkgo total lactones and add injection and blunge and make dissolving, filter, filtrate is boiled the active carbon that the back adds 0.6% (W/V), keep little and boiled 30 minutes, cold slightly filtration, filtrate adjust pH to 4.5～6.0, boil, coarse filtration, fine straining are spent the night in cold preservation (4 ℃); Mannitol is added the injection water be mixed with 120mg/ml solution,, filter, add the injection water, packing, lyophilization, pre-freeze temperature-45 ℃, pre-freeze time 10h to ormal weight with above-mentioned filtrate mixing; The beginning evacuation, and be warming up to-40 ℃, keep 8h; And in 12～72 hours differential gradient increased temperature to 10 ℃ progressively, keep 2h, be warming up to 20 ℃, keep 2h, be warming up to 30 ℃, keep 2h, promptly get the Injectable sterile block.
Embodiments of the invention 13: troxerutin 1g Folium Ginkgo total lactones 10g
Get troxerutin, add the injection water, stir and make it dissolving, medicinal liquid is standby; Get Folium Ginkgo total lactones, add injection and blunge and make dissolving, filter filtrate for later use; Above-mentioned two medicinal liquids are merged, and regulating pH value is 4.5～6.0, adds 0.6% activated needle-use activated carbon, boil absorption 30min, carbon removal, fine straining, filtrate adds the injection water to ormal weight, spend the night 4 ℃ of cold preservations, coarse filtration, fine straining divide to install in the ampoule bottle sterilization, packing promptly gets injection with small volume or concentrated solution for injection.
Embodiments of the invention 14: troxerutin 3g Folium Ginkgo total flavones, total lactone 45g
Get troxerutin and Folium Ginkgo total flavones and add injection and blunge and make dissolving, filter, filtrate is boiled the active carbon that the back adds 0.6% (W/V), keep little and boiled 30 minutes, cold slightly filtration, filtrate adjust pH to 4.5～6.0, boil, coarse filtration, fine straining are spent the night in cold preservation (4 ℃); Mannitol is added the injection water be mixed with 120mg/ml solution,, filter, add the injection water, packing, lyophilization, pre-freeze temperature-45 ℃, pre-freeze time 10h to ormal weight with above-mentioned filtrate mixing; The beginning evacuation, and be warming up to-40 ℃, keep 8h; And in 12～72 hours differential gradient increased temperature to 10 ℃ progressively, keep 2h, be warming up to 20 ℃, keep 2h, be warming up to 30 ℃, keep 2h, promptly get the Injectable sterile block.
Embodiments of the invention 15: troxerutin 10g Folium Ginkgo total lactones, total flavones 1g
Get troxerutin, add the injection water, stir and make it dissolving, medicinal liquid is standby; Get Folium Ginkgo total lactones, total flavones, add injection and blunge and make dissolving, filter filtrate for later use; Above-mentioned two medicinal liquids are merged, and regulating pH value is 4.5～6.0, adds 0.6% activated needle-use activated carbon, boil absorption 30min, carbon removal, fine straining, filtrate adds the injection water to ormal weight, spend the night 4 ℃ of cold preservations, coarse filtration, fine straining divide to install in the ampoule bottle sterilization, packing promptly gets injection with small volume or concentrated solution for injection.
Embodiments of the invention 16: troxerutin 1g Folium Ginkgo total flavones 10g
With Folium Ginkgo total flavones, troxerutin mix homogeneously, be dissolved in the phosphate buffer (0.1M) standby, a certain proportion of fabaceous lecithin, cholesterol are dissolved in the 18-amine. solution, add in the phosphate-buffered liquor of said medicine, the water-bath type Ultrasound Instrument is handled 10min, gets liposome turbid liquor, the phosphate buffer standardize solution, filtration sterilization, aseptic subpackaged, promptly get lipidosome injection.
Embodiments of the invention 17: troxerutin 10g Folium Ginkgo total lactones 30g
With Folium Ginkgo total lactones, troxerutin mix homogeneously, be dissolved in the phosphate buffer (0.1M) standby, a certain proportion of fabaceous lecithin, cholesterol are dissolved in the 18-amine. solution, add in the phosphate-buffered liquor of said medicine, the water-bath type Ultrasound Instrument is handled 8min, gets liposome turbid liquor, behind the frozen drying, cross 180 mesh sieves, aseptic subpackaged, promptly get the pro-liposome injectable powder.
Embodiments of the invention 18: troxerutin 10g Folium Ginkgo total flavones, total lactone 50g
With Folium Ginkgo total flavones, total lactone, the troxerutin mix homogeneously, be dissolved in the phosphate buffer (0.1M) standbyly, a certain proportion of fabaceous lecithin, cholesterol are dissolved in the 18-amine. solution, add in the phosphate-buffered liquor of said medicine, the water-bath type Ultrasound Instrument is handled 10min, get liposome turbid liquor, phosphate buffer standardize solution, filtration sterilization, aseptic subpackaged, promptly get lipidosome injection.
Troxerutin among the above embodiment is the commercial goods that can directly buy, Folium Ginkgo total flavones can be with commercially available or Radix Puerariae alcohol extract provided by the invention, water extract, water extract-alcohol precipitation extract, semi-bionic extraction thing, supercritical extract or the like, but: the content for flavones ingredient in the oral Folium Ginkgo total flavones is not less than 50%, and the content of flavones ingredient is not less than 70% in the Folium Ginkgo total flavones of injection.
Claims (11)
1, a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, it is characterized in that: calculate according to parts by weight, it is mainly to be made up of for 0.1～30 part 1 part of troxerutin and 0.1～50 part of Folium Ginkgo total flavones or 0.01～50 part of Folium Ginkgo total lactones or Folium Ginkgo total flavones and total lactone.
2, according to the pharmaceutical composition of the described treatment cardiovascular and cerebrovascular disease of claim 1, it is characterized in that: calculate according to parts by weight, it mainly is made up of for 0.1～15 part 1 part of troxerutin and 0.5～20 part of Folium Ginkgo total flavones or 0.1～10 part of Folium Ginkgo total lactones or Folium Ginkgo total flavones and total lactone.
3, according to the pharmaceutical composition of claim 1 or 2 described treatment cardiovascular and cerebrovascular diseases, it is characterized in that: calculate according to parts by weight, it mainly is made up of for 0.2～5 part 1 part of troxerutin and 1～10 part of Folium Ginkgo total flavones or 0.2～5 part of Folium Ginkgo total lactones or Folium Ginkgo total flavones and total lactone.
4, pharmaceutical composition according to any described treatment cardiovascular and cerebrovascular disease of claim 1～3 is characterized in that: described combination dosage form is the injection that is directly used in drug administration by injection, directly supply the venous transfusion of intravenous drip, need to be used for the concentrated solution for injection of intravenous drip and injectable sterile powder and aseptic block and the tablet that makes with freeze-drying or spray drying method after the dilution, capsule, granule, drop pill, pellet, pill, soft capsule, oral liquid, oral cavity disintegration tablet, dispersible tablet, membrane, all acceptable dosage forms on the pharmaceuticss such as sublingual lozenge.
5, according to the pharmaceutical composition of the described treatment cardiovascular and cerebrovascular disease of claim 4, it is characterized in that: described combination dosage form comprise the injection that is directly used in drug administration by injection, directly for the venous transfusion of intravenous drip, need to be used for after the dilution concentrated solution for injection of intravenous drip and the injectable sterile powder that makes with freeze-drying or spray drying method and aseptic block and drop pill, pellet, oral liquid, oral cavity disintegration tablet, dispersible tablet, sublingual lozenge.
6, according to the pharmaceutical composition of the described treatment cardiovascular and cerebrovascular disease of claim 4～5, it is characterized in that: described composite preparation can make on the basis that in troxerutin, Folium Ginkgo total flavones, the Folium Ginkgo total lactones one or more is prepared into liposome or pro-liposome.
7, according to the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease in the claim 1～6, it is characterized in that: Folium Ginkgo effective site is commercially available or adopts following method to prepare: get the Folium Ginkgo medical material, adding entry or alcoholic solution extracts, merge extractive liquid,, filter, filtrate concentrate the Radix Puerariae crude extract, adopt on this basis ethanol precipitation, water return in molten method, column chromatography, extraction, the flocculent precipitation one or more unite use carry out suitably refining, Folium Ginkgo total flavones effective site; Get the Folium Ginkgo medical material, adding entry or alcoholic solution extracts, merge extractive liquid,, filter, filtrate concentrate the Radix Puerariae crude extract, adopt on this basis ethanol precipitation, water return in molten method, column chromatography, extraction, the flocculent precipitation one or more unite use carry out suitably refining, Folium Ginkgo total lactones effective site.
8, according to the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease in the claim 4～6, it is characterized in that: the content sum of flavones ingredient and lactone composition is not less than in the preparation 50% of total solid after deduction troxerutin amount, pharmaceutical adjunct amount and the water quantities in the oral formulations, and the content sum of flavones ingredient and lactone composition is not less than 70% of total solid after deduction troxerutin amount, pharmaceutical adjunct amount and the water quantities in the ejection preparation; Troxerutin content should be 90.0%～110.0% of preparation labelled amount.
9, according to the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease in the claim 1～5, it is characterized in that: the Injectable sterile block prepares like this: one or both that get troxerutin and Folium Ginkgo total flavones, Folium Ginkgo total lactones add injection and blunge and make dissolving, filter, filtrate is boiled the active carbon that the back adds 0.6% (W/V), keeps little and boils 30 minutes, cold slightly filtration, filtrate adjust pH to 4.5～6.0, boil, coarse filtration, fine straining are spent the night in cold preservation (4 ℃); Mannitol is added the injection water be mixed with 120mg/ml solution,, filter, add the injection water, packing, lyophilization, pre-freeze temperature-45 ℃, pre-freeze time 10h to ormal weight with above-mentioned filtrate mixing; The beginning evacuation, and be warming up to-40 ℃, keep 8h; And in 12～72 hours differential gradient increased temperature to 10 ℃ progressively, keep 2h, be warming up to 20 ℃, keep 2h, be warming up to 30 ℃, keep 2h, promptly.
10, according to the application of the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease in the claim 1～6, it is characterized in that: described compositions is used for preparation treatment coronary heart disease, angina pectoris, cerebral thrombosis, alzheimer disease, cerebral vasospasm, thrombophlebitis, capillary hemorrhage, arteriosclerosis, diabetes and disease medicaments such as complication, hepatorenal syndrome thereof.
11, according to the method for quality control of the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease in the claim 4～6, it is characterized in that: this method comprises following all or part of content:
(1) finger printing test comprises that being characterized as the Folium Ginkgo terpene lactone constituents of advocating peace with the Folium Ginkgo flavone constituents is characterized as one or both of main finger printing;
(2) all or part of differential test method in Folium Ginkgo medical material, total flavonoids, terpene lactone, the troxerutin;
(3) content test method of all or part of composition in total flavonoids, terpene lactone, the troxerutin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510115004 CN1969892A (en) | 2005-11-23 | 2005-11-23 | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and quality control method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510115004 CN1969892A (en) | 2005-11-23 | 2005-11-23 | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and quality control method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1969892A true CN1969892A (en) | 2007-05-30 |
Family
ID=38111040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510115004 Pending CN1969892A (en) | 2005-11-23 | 2005-11-23 | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and quality control method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1969892A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112603998A (en) * | 2020-12-22 | 2021-04-06 | 黑龙江迪龙制药有限公司 | A compound preparation containing troxerutin for treating thrombi and its preparation method |
-
2005
- 2005-11-23 CN CN 200510115004 patent/CN1969892A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112603998A (en) * | 2020-12-22 | 2021-04-06 | 黑龙江迪龙制药有限公司 | A compound preparation containing troxerutin for treating thrombi and its preparation method |
| CN112603998B (en) * | 2020-12-22 | 2022-02-11 | 黑龙江迪龙制药有限公司 | A compound preparation containing troxerutin for treating thrombi and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1969897A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969927A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969892A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and quality control method thereof | |
| CN1981800A (en) | Chinese-medicinal preparation for treating cardiovascular diseases, its production and use | |
| CN1969946A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969939A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969947A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969926A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969919A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1981801A (en) | Chinese-medicinal preparation for treating cardiovascular diseases, its production and use | |
| CN1969916A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969938A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969899A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969917A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969902A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969898A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969977A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969967A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969978A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1961901A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961910A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1969905A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969966A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN100998622A (en) | Traditional Chinese medicine preparations for treating cardiovascular and cerebrovascular diseases the preparation method and use thereof | |
| CN1969912A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |